 To determine the efficacy of adding Isentress, with or without Celsentri, to effective conventional antiretroviral therapy comprising at least 2 reverse transcriptase inhibitors and one boosted protease inhibitor, on residual HIV replication and blood cell and gut-associated lymphoid tissue reservoirs reverse transcriptase inhibitors: RTIs, boosted protease inhibitors: PIr. 